January 2022

Civica by the Numbers

Delivering vital medications

72M
vials or syringes
of essential
generic medications
to treat over
28M
patients

Solving critical drug shortages

60
Generic medications
available from Civica
11
Medications used to treat Covid-19

Building innovative partnerships

55
Health System Members
15
Manufacturing Partners

March 2022

Civica to Manufacture and Distribute Affordable Insulin

Through a transformative collaboration between Civica and dedicated partners representing nearly every corner of the diabetes ecosystem, Americans with diabetes will have access to more affordable insulins. This transparent, cost-plus model will drastically reduce out-of-pocket costs for insulin.

“Diabetes is arguably America’s most expensive chronic condition, and it is heartbreaking that millions of people are rationing their care and putting their lives at risk because they can no longer afford insulin. Through mission-driven partnerships, we are choosing to create a new market reality where no one is forced to ration essential diabetes medications.”

Dan Liljenquist
Board Chair of Civica
Chief Strategy Officer, Intermountain Healthcare

Media Coverage

Civica to Manufacture and Distribute Affordable Insulin
A Group of Hospitals Has a Plan to Get Around Congress’s Refusal to Lower the Cost of Insulin

Civica Rx Thinks It Has a Cure for High Insulin Prices
abc4.com logo
CNN politics logo
The Washington Post logo
PharmaVoice logo

March 24, 2022

Civica Hill Briefing: Civica to Manufacture and Distribute Affordable Insulin

April 1, 2022

Insulin Has Been Around for 100 Years, So Why Is It Still So Expensive?

“Our objective is to generate a societal return, improving affordability and alleviating human suffering while demonstrating that market solutions exist that can help moderate the effects of capitalism unrestrained by notions of right and wrong—models that put the needs of the patient first and always.”

Dan Liljenquist,
Board Chair of Civica
Chief Strategy Officer, Intermountain Healthcare
Martin VanTrieste
Civica President and CEO

Media Coverage

Insulin Has Been Around for 100 Years, So Why Is It Still So Expensive?

April 1, 2022

Civica Leads Biggest Economic Development in Petersburg, Virginia, in 40 Years

United States Senator Tim Kaine (D-Va.) and Petersburg Mayor Sam Parham join Civica leaders on-site at Civica’s manufacturing plant under construction in Petersburg, Virginia to tour and learn more about the project’s impact not only on the local economy but also ultimately on lowering the cost of pharmaceuticals around the world.
On left, Civica CEO Martin VanTrieste and Sen. Kaine tour the new facility. On right, Civica team members include (from left) Engineering Lead Jason Winfield, Petersburg Site Head Stan Benson, CEO Martin VanTrieste, and Chief Quality and Regulatory Affairs Officer Donna Gulbinski.
On left and right, views from the construction of Civica’s manufacturing plant in Petersburg, Virginia.

April 6, 2022

A Radical Treatment for Insulin Pricing

“If Civica does deliver on its plan, it will disrupt the status quo for an important set of drugs and establish a path for reducing prices for other biologic medications whose market exclusivity periods have passed.”

NEJM OpEd

Media Coverage

A Radical Treatment for Insulin Pricing
The New England Journal of Medicine logo

April 26, 2022

Diabetes Connections: We Can Do It – Civica Rx and Non-Profit Insulin

Hear from Civica Chief Operating Officer Ned McCoy on Civica’s plans to manufacture and sell three types of insulin for one low-cost to patients who require it – regardless of insurance coverage.

May 24, 2022

Civica Announces Leadership Transition

Effective June 1, Ned McCoy, formerly Civica’s Chief Operating Officer, succeeds Martin VanTrieste as Civica’s President and Chief Executive Officer. Martin remains an advisor to the Company and continues serving on Civica’s Board of Directors. As part of this transition, Ned also joins the Civica Board of Directors.

“I look forward to continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”

Ned McCoy
Civica President and Chief Executive Officer

Media Coverage

Civica Announces Leadership Transition
Civica Taps Current COO to Succeed VanTrieste as Chief Executive
Civica Taps Ned McCoy as New CEO
Civica Rx COO McCoy to Step into CEO Role from 1 June
Civica Names Ned McCoy as its CEO
Civica Selects Next CEO

June 1, 2022

A Conversation with Civica’s Affordable Insulin Initiative Leader

“Civica’s insulin project will ensure that patients have the capability to manage their insulin by making it available and affordable to all who need it.”

Tom Damratoski
Senior Vice President, Biopharmaceutical Products

June 2, 2022

Profil Selected as Clinical Trial Partner for Affordable Insulin Initiative

Civica chose Profil as clinical trial partner to support the development of its affordable insulin biosimilars. Profil is the leading clinical research organization for studies related to diabetes and obesity.

Media Coverage

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative
Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative
Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative
Civica Signs Up Profil to Run Trials for Affordable Insulin Biosimilars
Civica Nabs Trial Partner as It Forges Ahead to Create More Affordable Insulins
Morningstar logo
BioSpace logo
Fierce Healthcare logo
Endpoints News logo

June 14, 2022

Civica’s Sister Organization CivicaScript™ Welcomes New Members

CivicaScript™, Civica’s sister organization focused on lower prices at the pharmacy counter, welcomes new members EmsanaRx and Health Care Service Corporation.

Media Coverage

EmsanaRx Joins CivicaScript™ to Make Lower-Cost Generic Medicines Available to its Pharmacy Benefit Members
Health Care Service Corporation Joins CivicaScript™ to Make Lower-Cost Generic Medicines Available to its Members

June 15, 2022

A Dose of Prescription Drug Disruption

Gina Guinasso, President at CivicaScript, talks about the exorbitant costs in today’s prescription drugs and how her organization – together with the industry – is leveling the playing field by distributing generic drugs directly to pharmacies.

June 30, 2022

Civica Joins the End Drug Shortages Alliance

Shortages of generic drugs critical to the lifesaving work of hospitals in the U.S. have become far too commonplace. Working to solve this issue, Civica has joined the End Drug Shortages Alliance, a new coalition of diverse stakeholders to address drug shortages in the United States.

Media Coverage

Civica Joins the End Drug Shortages Alliance
End Drug Shortages Alliance logo

July 2022

And So It Begins – Equipment Arrives at Civica Manufacturing Plant

The equipment to fill vials of affordable insulin and essential medicines used for critical patient care in hospitals arrived in July at our Civica Rx manufacturing plant in Petersburg, Virginia. Watch it leaving Germany…

Thank you to groninger & co. gmbh, CRB and SKAN AG for their partnership in getting us to this milestone. We look forward to the day when this vial line will help us ensure quality medicines are available and affordable across the country.

July 13, 2022

Navitus Health Solutions Joins CivicaScript™

Navitus Health Solutions joins CivicaScript™ as a founding member. An industry-disrupting pharmacy benefit manager (PBM), Navitus is committed to bringing humanity to pharmacy benefits management through greater transparency and affordability.

CivicaScript and Navitus partnership

Media Coverage

Navitus Health Solutions Joins CivicaScript™ to Further Availability of Lower-Cost Generic Medications
Navitus Health Solutions Signs on with CivicaScript to Address High-cost Generics
Fierce Healthcare Logo

July 21, 2022

Mayo Clinic Q&A Podcast: Combating Drug Shortages

Civica is mentioned as a solution.

July 25, 2022

“20 to Watch” from Fierce Healthcare

Civica President and CEO Ned McCoy is one of 20 executives recognized by Fierce Healthcare as leaders who are on the front line of the healthcare industry evolution.

Read more here

Civica President and CEO Ned McCoy

“Civica’s insulin project will ensure that patients have the capability to manage their insulin by making it available and affordable to all who need it.”

Ned McCoy
President and CEO
Fierce Healthcare logo

August 3, 2022

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

CivicaScript™ launches its first product: abiraterone acetate 250 mg tablets. Abiraterone is used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body. The cost? As much as $3,000 per month less than the average cost for someone with Medicare Part D, the type of insurance people with prostate cancer are most likely to have.

Media Coverage

CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings
Civica Rx Begins Selling its First Outpatient Generic Drug as It Tries to Overhaul the Pharmaceutical Supply Chain
CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings
CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings
Generic Prostate-Cancer Drug Backed by Hospital Group Goes on Sale
STAT logo
Bloomberg logo
1stOncology logo
The Wall Street Journal logo

September 6, 2022

Civica Turns 4!

Since our founding in 2018, we have secured supplies of essential generic medicines in hospitals across the country, used to treat nearly 40 million patients. With our partners and our talented, dedicated team, we celebrate this work and look ahead towards expanding our focus to deliver insulin and other critical medicines at affordable prices. We will always do what is in the best interest of patients.

Learn more about our journey at Timeline – Civica Rx.

September 8, 2022

Civica to Expand in Greater Richmond-Petersburg Region, Investing in New Testing Facility

Civica announces the construction of a 55,000 square foot facility to support the company’s Petersburg manufacturing operation through quality testing and development of new products. The project will create 51 new jobs.

“With this investment, Civica is building on its long-term commitment to patients – and to Virginia. This lab will support a skilled and highly trained workforce who will ensure Civica’s affordable insulin as well as other essential medicines meet the highest standards.”

Ned McCoy
Civica President and Chief Executive Officer

Media Coverage

Civica Inc. to Expand in Greater Richmond—Petersburg Region, Investing $27.8 Million for a New Testing Facility
Civica Inc. to Expand in Greater Richmond—Petersburg Region, Investing $27.8 Million for a New Testing Facility
Pharma Partnership to Get Boost with New Labs in Richmond, Chesterfield
One Town in Virginia is Set to Become a U.S. Hub to Fill Generic Drug Gap
Greater Richmond Partnership logo
wbur logo
Richmond Bizsense logo

September 9, 2022

Insulin Spending Caps Won’t Work. Here’s a Better Idea

With fairer rules in place, competitors should be able to force down the cost of insulin overall, to the benefit of consumers and taxpayers alike. Wherever possible, the goal should be removing impediments… and making it harder for the major manufacturers to maintain the status quo.

Media Coverage

Insulin Spending Caps Won’t Work. Here’s a Better Idea
Bloomberg logo

September 12, 2022

Insulin Costs Increased 600% Over the Last 20 Years. States Aim to Curb the Price

As leading manufacturers have increased prices of insulin by more than 600% over the last 20 years, many diabetes patients ration this lifesaving drug. So who’s helping?

October 2022

Civica by the Numbers

Delivering vital medications

100M
vials or syringes
of essential
generic medications
to help treat over
40M
patients

beam/signing

“It’s more than a steel beam, it’s building the foundation for quality and affordable medication for millions of Americans.”

Dan Liljenquist
Chair, Civica Board of Directors

“This beam will cherish the names of Civica employees, partners, and visitors and be a daily reminder of just how many people we are helping to build a better tomorrow…

“Civica Rx has already partnered with nearly 60 health systems, over 1,500 hospitals, and produced more than 60 drugs. This facility, set in Virginia, will help produce insulin and lower the cost from $300 to $30 per vial. It will also produce numerous essential medicines hospitals rely on every day. On top of all that, the facility itself is helping to give more sustainable jobs and incomes for families in the area.”

November/December 2022

Late-stage construction of the Civica Rx Petersburg VA manufacturing facility is well underway. And the facility now has a name.

With our hospital, philanthropy, government and manufacturing partners we are reducing drug shortages and avoiding predatory pricing. This facility will enable us to do more.

With CivicaScript and our partners in the diabetes, philanthropy, payor, health system, manufacturing and clinical trial communities, we are working to make this facility the future home of affordable insulin.

We are grateful for the warm welcome we are receiving from the greater Richmond and Petersburg communities and look forward to our continued collaboration.

Here’s the road to the future home of affordable insulin and essential sterile injectable medicines hospitals rely on every day.

The new address of our Civica Petersburg manufacturing facility is “One Civica Way”

Civica Petersburg address: One Civica Way

Media Coverage

Civica’s 2023 plans: Full steam ahead on Virginia plant, insulins

Stay tuned!

The members section is currently being built, based on feedback from users like yourself.

login

Not a member yet? Get information on joining here.